Rituximab for PTLD of the CNS: is it a 'no-brainer'?
Reshef
Ran
R
Tsai
Donald E
DE
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001927:Brain Diseases / Q000188:drug therapy* / Q000209:etiology*; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis* / Q000209:etiology*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000209:etiology*; D000069283:Rituximab; D019737:Transplants / Q000009:adverse effects*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab